The life cycle of extracellular vesicles in prostate cancer: from biogenesis and homing, to functional relevance.
Training programme focusing on understanding the role of extracellular vesicles in prostate cancer.
Human R&D, Training, Project Management
H2020-MSCA-ITN-2019 – Grant agreement ID 860303
1 October 2019 to 30 September 2023
Prostate cancer (PCa) presents as a major health care problem for men, with EU-wide approximately 365,000 new cases annually. Current means to identify rapid from slow progressing tumors are lacking specificity. There is an unmet need to means of non-invasive discrimination of these tumors and identification of novel targets for therapeutic intervention of high-risk tumors. The potential of EVs as minimal or non-invasive biomarkers and therapy targets/agents are a growing area of interest. The proEVLifeCycle project aims to aid to the understanding of PCa progression and consequently, to the implementation of novel biomarkers and therapeutic interventions to have a lasting impact on this indiscriminate and lethal disease. Any relief in the burden of this disease will have major impact on the huge socio-economic problems for patients, families, caregivers, and society. The ambitious scientific objectives are to unravel the mysteries of EV biogenesis, homing and uptake to explain how vesicles operate in disease processes; their heterogeneity, their molecular complexity, the biological functions they drive, their local and systemic dissemination and how these may be manipulated. Using state-of-the-art, network-wide shared model systems, imaging and profiling tools, and systems biology, the program will enlighten the lifecycle of EVs and identify novel EV biomarkers and PCa therapy targets to address the unmet clinical needs. GenomeScan, apart from hosting an early stage researcher (ESR), provides Next Generation Sequencing (NGS) services and Bio-IT analyses aiming to evaluate EV potential. Further, our company leads the work package dealing with the project’s dissemination and communication efforts.
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling. Van Hemelryk A, et al. Cells. 2022 Nov 16;11(22):3632. doi: 10.3390/cells11223632
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860303.